Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HYPOVACC

Financiado

Cerrado

Hydrogel Polymersome based Subunit Vaccines in the Fight Against COVID 19

In light of current events, developing new technologies for the fight against severe infectious diseases, such as the COVID-19 pandemic caused by the SARS-CoV-2 virus, is a global health emergency. Despite the tremendous improveme... ver más

31/01/2025

UBx

258K€

Presupuesto del proyecto: 258K€

Líder del proyecto

UNIVERSITE DE BORDEAUX No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2025-01-31

MSCA-IF-2020: Individual Fellowships Objective:The goal of the Individual Fellowships is to enhance the creative and innovative potential...

I+D

Cerrada hace 4 años

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UBx

257.62K€ | Lider

BOARD OF TRUSTEES OF THE LEL...

STANFORD

165.27K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 46 meses Fecha Inicio: 2021-03-22
Fecha Fin: 2025-01-31

Líder del proyecto

UNIVERSITE DE BORDEAUX No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 258K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In light of current events, developing new technologies for the fight against severe infectious diseases, such as the COVID-19 pandemic caused by the SARS-CoV-2 virus, is a global health emergency. Despite the tremendous improvement of vaccine technologies, the design of potent, durable and safe vaccines displaying an ease of distribution and a reduced cost, remains a major technological challenge. This research project proposes to develop a novel biocompatible, injectable and scalable vaccine technology based on supramolecular hydrogels-containing polymersomes to enable a controlled local vaccine exposure for durable and broadly protective immune response against the SARS-CoV-2 infection. The platform will leverage supramolecular hydrogels as depot carriers for a sustained co-release of complex mixtures of immunomodulatory compounds comprising a typical vaccine and polymersomes to enhance the presentation of subunit antigens. Immunogenicity will be improved through potent immune stimulating-adjuvants mixtures, selected from a precise screening of vastly different molecules in terms of chemical nature and size, and a controlled multipresentation of antigens by fine-tuned antigen-grafted polymersomes. This highly innovative project will cover various disciplines ranging from chemistry, material science, to bioengineering, and will use new polymersomes and hydrogels constructs, vaccine technology and recently developed immunological assays. The proposal will be conducted in two internationally recognized leading teams in the field of drug delivery systems in Bordeaux University, France and Stanford University, USA. The international exposure and the outstanding scientific environment gained through the fellowship will be a key step for the independence and maturity of the researcher. She will acquire a unique multidisciplinary research profile which will be of significant interest for her future independent career in Europe.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores